GSK-2336805

Research use only, not for human use.

GSK-2336805 (JNJ-56914845) is a novel potent HCV NS5A inhibitor with multigenotype activity.

GSK-2336805 (JNJ-56914845) is a novel potent HCV NS5A inhibitor with multigenotype activity, has EC50s of 58.5, 7.4, and 53.8 pM on genotype 1a (H77), genotype 1b (Con-1 ET), and genotype 2a (JFH-1) replicon cells; shows an average EC50 of 63.7 pM on genotype 2a Jc1 virus, inhibits the HCV replication cycle and production of virus; retains activity on chimeric replicons containing NS5A patient sequences from genotype 1 and patient and consensus sequences for genotypes 4 and 5 and part of genotype 6.HCV Infection Phase 2 Clinical.

——

——

JNJ-56914845 | GSK2336805 | JNJ56914845

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

1256390-53-0

796.926

C42H52N8O8

>98% (HPLC)

——

O=C(OC)N[C@@H](C(C)C)C(N([C@H](C1=NC(C2=CC=C(C3=CC=C(C4=CNC([C@H]5N(C([C@H](C(C)C)NC(OC)=O)=O)CCC5)=N4)C=C3)C=C2)=CN1)C6)CC76OCCO7)=O

methyl ((S)-1-((S)-8-(4-(4'-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-4-yl)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate

(-20℃)

With Ice Pack

≥ 2 years